↓ Skip to main content

American College of Cardiology

Article Metrics

Drugs, Devices, and the FDA: Part 1

Overview of attention for article published in JACC: Basic to Translational Science, April 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#5 of 251)
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
23 news outlets
blogs
1 blog
twitter
20 tweeters
facebook
1 Facebook page
video
1 video uploader

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
155 Mendeley
Title
Drugs, Devices, and the FDA: Part 1
Published in
JACC: Basic to Translational Science, April 2016
DOI 10.1016/j.jacbts.2016.03.002
Pubmed ID
Authors

Gail A. Van Norman

Abstract

Over the last 150 years, the U.S. Food and Drug Administration (FDA) has evolved from a small division of the U.S. Patent Office to 1 of the largest consumer protection agencies in the world. Its mission includes ensuring that new medical treatments reach the public as quickly as possible while simultaneously ensuring that new treatments are both safe and effective. In the face of urgent consumer need, the FDA has faced criticism that its processes are too lengthy and costly and that the time to new drug release is significantly longer in the United States than in other Western countries. Calls from the public to loosen FDA regulations to facilitate more rapid approval of drugs and devices have been countered by the occurrence of patient harm and deaths after some approved drugs have reached the marketplace. New drug and device approval in the United States take an average of 12 and 7 years, respectively, from pre-clinical testing to approval. Costs for development of medical devices run into millions of dollars, and a recent study suggests that the entire cost for a new drug is in excess of $1 billion. For investigators seeking approval for new drugs and devices, FDA processes can be formidable. This 2-part series is intended to provide an overview of the steps involved in bringing new drugs and devices through the FDA process. Part 1 concerns the process of new drug approvals. Part 2 continues with approval of medical devices.

Twitter Demographics

The data shown below were collected from the profiles of 20 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 155 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 155 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 31 20%
Student > Ph. D. Student 30 19%
Student > Master 28 18%
Unspecified 22 14%
Researcher 16 10%
Other 28 18%
Readers by discipline Count As %
Unspecified 28 18%
Agricultural and Biological Sciences 22 14%
Engineering 19 12%
Biochemistry, Genetics and Molecular Biology 17 11%
Pharmacology, Toxicology and Pharmaceutical Science 17 11%
Other 52 34%

Attention Score in Context

This research output has an Altmetric Attention Score of 197. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 June 2019.
All research outputs
#64,724
of 13,210,683 outputs
Outputs from JACC: Basic to Translational Science
#5
of 251 outputs
Outputs of similar age
#2,727
of 263,421 outputs
Outputs of similar age from JACC: Basic to Translational Science
#1
of 17 outputs
Altmetric has tracked 13,210,683 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 251 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 19.8. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,421 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.